Table 2.

Comparison of clinical outcomes between the GnRH agonist long-acting protocol and GnRH antagonist protocol and after PS matching.

	Before matching			after matching
	GnRH antagonist	GnRH agonist	P value	GnRH antagonist	GnRH agonist	P value
Number of retrieved oocytes	9.30 ± 4.37	9.73 ± 4.22	<0.001*	9.16 ± 4.28	9.69 ± 4.22	<0.001*
Number of MII oocytes	8.17 ± 3.99	8.57 ± 3.90	<0.001*	8.05 ± 3.91	8.51 ± 3.90	<0.001*
Number of 2PN embryos	6.13 ± 3.37	6.14 ± 3.29	0.941	6.05 ± 3.32	6.07 ± 3.27	0.802
b OHSS rate	2.13% (77/3607)	4.42% (220/4972)	<0.001*	1.91% (63/3304)	4.57% (151/3304)	<0.001*
b Live birth	38.70% (1396/3607)	45.09% (2242/4972)	<0.001*	38.32% (1266/3304)	44.04% (1455/3304)	<0.001*
b biochemical pregnancy	55.78% (2012/3607)	61.38% (3052/4972)	<0.001*	55.75% (1842/3304)	60.90% (2012/3304)	<0.001*
b Clinical pregnancy	47.91% (1728/3607)	53.74% (2672/4972)	<0.001*	47.79% (1579/3304)	53.03% (1752/3304)	<0.001*
b ectopic pregnancy	3.99% (69/1728)	1.46% (39/2672)	<0.001*	4.12% (65/1579)	1.43% (25/1752)	<0.001*
b Early Miscarriage	13.54% (234/1728)	13.14% (351/2672)	0.699	14.06% (222/1579)	13.87 (243/1752)	0.875
b Late Miscarriage	2.26% (39/1728)	1.72% (46/2672)	0.208	2.28% (36/1579)	1.94% (34/1752)	0.495

MII, metaphase II; 2PN, 2 pronuclear; OHSS, ovarian hyperstimulation syndrome;

Data are presented as mean ± SD and n (%).

Student’s t-tests and Chi-square test were used for comparison of clinical outcomes between the two groups.

^*Statistically significant (P < 0.05).